Jose Lutzky on Proactively Monitoring Patients Receiving Immunotherapy Treatments

Tremelimumab plus durvalumab (STRIDE) showed a manageable immune-related adverse event profile in the phase 3 HIMALAYA trial.

Amber Pierce RN, BSN, OCN, highlights the importance of a 2-step verification process with fixed-dose regimen therapies.

Cemiplimab has received full approval for patients with metastatic basal cell carcinoma. The most common adverse events include fatigue, musculoskeletal pain, rash, diarrhea, and anemia.

Krista M. Rubin, RN, MS, FNP-BC, highlights how nurses can help patients with uveal melanoma anticipate and manage adverse events during the step-up dosing period with tebentafusp.

Combined adjuvant treatment with mRNA-4157 in combination with pembrolizumab improved recurrence rates in patients with resected high-risk melanoma.

Patients who received pembrolizumab plus cisplatin and gemcitabine achieved a median overall survival of 12.7 months, compared with 10.9 months with cisplatin and gemcitabine alone.